1. Home
  2. SID vs GLPG Comparison

SID vs GLPG Comparison

Compare SID & GLPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Companhia Siderurgica Nacional S.A.

SID

Companhia Siderurgica Nacional S.A.

HOLD

Current Price

$1.86

Market Cap

2.1B

Sector

Industrials

ML Signal

HOLD

Logo Galapagos NV

GLPG

Galapagos NV

HOLD

Current Price

$33.01

Market Cap

2.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SID
GLPG
Founded
1941
1999
Country
Brazil
Belgium
Employees
N/A
N/A
Industry
Steel/Iron Ore
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.1B
2.1B
IPO Year
1997
2005

Fundamental Metrics

Financial Performance
Metric
SID
GLPG
Price
$1.86
$33.01
Analyst Decision
Strong Sell
Hold
Analyst Count
1
4
Target Price
$1.40
$31.33
AVG Volume (30 Days)
3.0M
99.7K
Earning Date
11-04-2025
02-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$8,522,708,358.00
$336,643,201.00
Revenue This Year
$4.93
$1.76
Revenue Next Year
N/A
$0.49
P/E Ratio
N/A
N/A
Revenue Growth
4.02
10.31
52 Week Low
$1.24
$22.36
52 Week High
$1.88
$37.78

Technical Indicators

Market Signals
Indicator
SID
GLPG
Relative Strength Index (RSI) 63.56 58.80
Support Level $1.60 $32.33
Resistance Level $1.88 $33.91
Average True Range (ATR) 0.06 0.72
MACD 0.02 0.03
Stochastic Oscillator 88.33 62.13

Price Performance

Historical Comparison
SID
GLPG

About SID Companhia Siderurgica Nacional S.A.

Companhia Siderurgica Nacional is an integrated steel producer. together with its subsidiaries operates in five main business segments: Steel industry: production and marketing of flat and long steels; Mining: extraction, processing and marketing of iron ore, tin, limestone and dolomite; Cement: production and commercialization of bagged and bulk cement, in addition to aggregates, concrete, and other related products; Energy: generation and sale of energy from almost all renewable sources; and Logistics: participations in railways and port terminals. The group generates the majority of its revenue from the Steel industry segment. Geographically, it derives a majority of revenue from Asia.

About GLPG Galapagos NV

Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.

Share on Social Networks: